Atsushi Fukatsu
Overview
Explore the profile of Atsushi Fukatsu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
76
Citations
1754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Inada A, Fukatsu A
Am J Physiol Renal Physiol
. 2023 Aug;
325(5):F527-F535.
PMID: 37615048
Hypoxia and oxidative stress are considered to be underlying factors in the deterioration of renal function and pathogenesis in acute kidney injury (AKI) and chronic kidney disease, including diabetic nephropathy...
2.
Inada A, Inada O, Yasunami Y, Arakawa K, Nabeshima Y, Fukatsu A
Am J Pathol
. 2022 Apr;
192(7):1028-1052.
PMID: 35460614
Diabetic nephropathy (DN), once manifested, is unlikely to completely recover. Factors that influence DN progression were explored by investigating the process of glomerulosclerosis and interstitial fibrosis and chronological changes in...
3.
Kozaki Y, Morinaga T, Fukatsu A, Ito T, Ishimoto T, Kosugi T, et al.
Clin Exp Nephrol
. 2022 Jan;
26(5):466-475.
PMID: 35048329
Background: A Dialysis Outcomes and Practice Patterns Study (DOPPS) has shown a one-to-one male-to-female mortality ratio, notwithstanding the statistically longer life expectancy of women in the general population. This finding...
4.
Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, et al.
Clin Pharmacol Drug Dev
. 2018 Apr;
7(8):820-828.
PMID: 29693800
This open-label, parallel-group, multicenter study aimed to assess the effects of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of luseogliflozin. A single 5-mg dose of luseogliflozin was administered to...
5.
Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S
Curr Med Res Opin
. 2018 Feb;
34(6):981-994.
PMID: 29448833
Objective: To evaluate the efficacy and safety of luseogliflozin in Japanese patients with type 2 diabetes (T2D) inadequately controlled with insulin monotherapy. Methods: This 52-week multicenter study entailed a 16-week,...
6.
Seino Y, Yabe D, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, et al.
J Diabetes Investig
. 2017 May;
9(2):332-340.
PMID: 28502112
Aims/introduction: The aim of the present study was to evaluate the safety and efficacy of luseogliflozin added to liraglutide monotherapy in Japanese individuals with type 2 diabetes. Materials And Methods:...
7.
Araki M, Matsubara T, Abe H, Torikoshi K, Mima A, Iehara N, et al.
Sci Rep
. 2016 Aug;
6:31216.
PMID: 27492138
Matrix expansion and cell proliferation are concomitantly observed in various glomerular injuries. However, the molecular mechanisms responsible for these changes have not been fully elucidated. We have reported that Smad1...
8.
Ameku T, Taura D, Sone M, Numata T, Nakamura M, Shiota F, et al.
Sci Rep
. 2016 Jul;
6:30013.
PMID: 27418197
Cardiovascular complications are the leading cause of death in autosomal dominant polycystic kidney disease (ADPKD), and intracranial aneurysm (ICA) causing subarachnoid hemorrhage is among the most serious complications. The diagnostic...
9.
Matsumoto T, Iyomasa S, Fukatsu A
World Hosp Health Serv
. 2016 May;
52(1):11-3.
PMID: 27180467
Anjo City has two general hospitals. Kosei Hospital, a central medical center for advanced care, and our Yachiyo Hospital for regional care. Recently, Kosei Hospital faced over-capacity problem because of...
10.
Sakai S, Kaku K, Seino Y, Inagaki N, Haneda M, Sasaki T, et al.
Clin Ther
. 2016 Mar;
38(4):843-862.e9.
PMID: 27021608
Purpose: Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, may be beneficial in obese diabetic patients based on its potential to decrease blood glucose and body weight, but there is limited proof. This...